DLA-identical bone marrow grafts after low-dose total body irradiation: effects of high-dose corticosteroids and cyclosporine on engraftment.

Previous studies found that marrow allografts from DLA-identical littermates resulted in survival of 60% of recipient dogs after an otherwise lethal dose of 450 cGy of total body irradiation (TBI), either because of successful allografts or autologous recovery after rejection of the allografts. Forty percent of dogs died with marrow aplasia after allograft rejection. The current study asked whether allogeneic engraftment could be enhanced and survival improved by treating allograft recipients with high doses of corticosteroids or with cyclosporine (CSP), administered either before or after transplantation. Five dogs in group 1 received corticosteroids beginning on day -5 and ending on day 32 after transplant. The starting dose was 12.5 mg of prednisone per kilogram orally twice daily. All five dogs rejected their allografts; three died early with marrow aplasia and two showed endogenous marrow recovery. Nine dogs received CSP from day -6 to day -1 before transplantation at a dose of 20 mg/kg/d intravenously administered in divided doses. All nine dogs rejected the marrow allograft; six died with marrow aplasia and three survived with endogenous marrow recovery. Seven dogs received CSP after transplantation at a dose of 30 mg/kg/d orally from day -1 to day 35. All seven had sustained allografts (two mixed chimeras and five complete donor-type chimeras) and became healthy long-term survivors without graft-versus-host disease. These results extend previous observations and confirm that grafts of marrow from DLA-identical littermates improved survival of dogs exposed to low but otherwise lethal doses of TBI. Additional therapy with high-dose corticosteroids administered peritransplantation and posttransplantation or CSP administered before transplantation neither enhanced the rate of allogeneic engraftment nor improved survival; however, CSP administered after transplantation resulted in successful allografts and event-free survival in all cases.

[1]  H. Deeg,et al.  DLA-identical marrow grafts after low-dose total-body irradiation. Addition of viable donor peripheral blood mononuclear cells does not enhance engraftment. , 1995, Transplantation.

[2]  H. Deeg,et al.  DLA-identical bone marrow grafts after low-dose total body irradiation: the effect of canine recombinant hematopoietic growth factors. , 1994, Blood.

[3]  E. Bryant,et al.  USE OF (CA)n POLYMORPHISMS TO DETERMINE THE ORIGIN OF BLOOD CELLS AFTER ALLOGENEIC CANINE MARROW GRAFTING , 1994, Transplantation.

[4]  B. Sandmaier,et al.  'Resistance' to unrelated, DLA-nonidentical canine marrow grafts is unrestricted by the major histocompatibility complex. , 1994, Experimental hematology.

[5]  R. Storb,et al.  A simple restriction fragment-length polymorphism assay for MHC class II gene testing of dog families. , 1994, Transplantation.

[6]  H. Deeg,et al.  Fractionated versus single-dose total body irradiation at low and high dose rates to condition canine littermates for DLA-identical marrow grafts. , 1994, Blood.

[7]  H. Deeg,et al.  Marrow toxicity of fractionated vs. single dose total body irradiation is identical in a canine model. , 1993, International journal of radiation oncology, biology, physics.

[8]  J. E. Wagner.  PREVENTION OF GRAFT FAILURE BY CYCLOSPORINE IN RATS RECEIVING LYMPHOCYTE‐DEPLETED MHC‐MISMATCHED BONE MARROW , 1992, Transplantation.

[9]  H. Deeg,et al.  Changing trends in marrow transplantation for aplastic anemia. , 1992, Bone marrow transplantation.

[10]  W. Mueller-Ruchholtz,et al.  Effect of post-transplant methotrexate, cyclosporin A and prednisolone on graft rejection after allogeneic bone marrow transplantation. , 1991, Bone marrow transplantation.

[11]  Brenda,et al.  Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: I. Analysis of risk factors and results of secondary transplants. , 1989, Blood.

[12]  M. Pepe,et al.  Comparison of fractionated to single-dose total body irradiation in conditioning canine littermates for DLA-identical marrow grafts. , 1989, Blood.

[13]  R. Storb,et al.  What radiation dose for DLA-identical canine marrow grafts? [published erratum appears in Blood 1989 Feb;73(2):624] , 1988 .

[14]  B. Sandmaier,et al.  What radiation dose for DLA-identical canine marrow grafts? , 1988, Blood.

[15]  T. MacVittie,et al.  Improved survival of dogs exposed to fission neutron irradiation and transplanted with DLA identical bone marrow. , 1987, Bone marrow transplantation.

[16]  K. Bradstock,et al.  Resistance to engraftment in irradiated dogs receiving T cell-depleted bone marrow transplants. , 1987, Transplantation proceedings.

[17]  H. Deeg,et al.  JOINT REPORT OF THE THIRD INTERNATIONAL WORKSHOP ON CANINE IMMUNOGENETICS: II. ANALYSIS OF THE SEROLOGICAL TYPING OF CELLS , 1987, Transplantation.

[18]  H. Deeg,et al.  FAILURE OF ALLOGENEIC CANINE MARROW GRAFTS AFTER TOTAL‐BODY IRRADIATION: ALLOGENEIC “RESISTANCE” VERSUS TRANSFUSION‐INDUCED SENSITIZATION , 1986, Transplantation.

[19]  R. Storb,et al.  Mixed Hematologic Chimerism After Allogeneic Marrow Transplantation for Severe Aplastic Anemia Is Associated With a Higher Risk of Graft Rejection and a Lessened Incidence of Acute Graft-Versus-Host Disease , 1986 .

[20]  R. Storb,et al.  Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease. , 1986, Blood.

[21]  E. Gordon-Smith,et al.  Cyclosporine and graft failure following bone marrow transplantation for severe aplastic anaemia , 1985, British journal of haematology.

[22]  D. V. van Bekkum,et al.  Factors controlling the engraftment of transplanted dog bone marrow cells. , 2008, Tissue antigens.

[23]  H. Deeg,et al.  Acute and chronic graft-versus-host disease in dogs given hemopoietic grafts from DLA-nonidentical littermates. Two distinct syndromes. , 1982, The American journal of pathology.

[24]  H. Deeg,et al.  Cyclosporin-A abrogates transfusion-induced sensitization and prevents marrow graft rejection in DLA-identical canine littermates. , 1982, Blood.

[25]  H. Deeg,et al.  CYCLOSPORIN A AND METHOTREXATE IN CANINE MARROW TRANSPLANTATION: ENGRAFTMENT, GRAFT‐VERSUS-HOST DISEASE, AND INDUCTION OF TOLERANCE , 1982, Transplantation.

[26]  R. Storb,et al.  Pathology of acute graft-versus-host disease in the dog. An autopsy study of ninety-five dogs. , 1979, The American journal of pathology.

[27]  G. Sale,et al.  HISTOPATHOLOGY OF HEPATIC ACUTE GRAFT‐VERSUS-HOST DISEASE IN THE DOG A DOUBLE BLIND STUDY CONFIRMS THE SPECIFICITY OF SMALL BILE DUCT LESIONS , 1978, Transplantation.

[28]  R. Storb,et al.  Marrow infusions in dogs given midlethal or lethal irradiation. , 1970, Radiation research.